Fate Therapeutics (FATE) to Release Quarterly Earnings on Wednesday
Fate Therapeutics (NASDAQ:FATE) is set to issue its quarterly earnings data after the market closes on Wednesday, February 24th. Analysts expect the company to announce earnings of ($0.38) per share for the quarter.
Shares of FATE stock opened at $110.18 on Friday. The stock has a fifty day moving average price of $102.60 and a 200 day moving average price of $64.38. The stock has a market cap of $9.61 billion, a PE ratio of -59.88 and a beta of 1.88. Fate Therapeutics has a 1 year low of $16.75 and a 1 year high of $121.16.
FATE has been the subject of several recent research reports. Smith Barney Citigroup raised their price target on Fate Therapeutics from $63.00 to $76.00 in a research report on Monday, December 7th. Piper Sandler raised their price target on Fate Therapeutics from $99.00 to $116.00 and gave the stock an “overweight” rating in a research report on Wednesday. Zacks Investment Research raised Fate Therapeutics from a “sell” rating to a “hold” rating and set a $108.00 price target for the company in a research report on Friday, February 12th. Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell raised their price target on Fate Therapeutics from $63.00 to $76.00 in a research report on Monday, December 7th. Finally, Barclays raised their price target on Fate Therapeutics from $110.00 to $130.00 and gave the stock an “overweight” rating in a research report on Friday, January 15th. Four research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $80.63.
In other Fate Therapeutics news, CEO J Scott Wolchko sold 30,000 shares of the business’s stock in a transaction dated Thursday, January 21st. The stock was sold at an average price of $103.05, for a total transaction of $3,091,500.00. Following the transaction, the chief executive officer now owns 393,793 shares in the company, valued at $40,580,368.65. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Redmile Group, Llc acquired 327,485 shares of Fate Therapeutics stock in a transaction on Friday, January 8th. The shares were bought at an average price of $85.50 per share, for a total transaction of $27,999,967.50. The disclosure for this purchase can be found here. In the last three months, insiders have sold 226,651 shares of company stock valued at $25,943,119. 21.41% of the stock is owned by company insiders.
Fate Therapeutics Company Profile
Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development includes FT516 for the treatment of acute myeloid leukemia (AML) and B-cell lymphoma, FT596 to treat B-cell lymphoma and CLL, FT538 to treat AML and multiple myeloma, FT576 to treat multiple myeloma, FT819 to treat B-cell malignancies, and FT-ONO1 to treat hematologic malignancies; and FT500, FT516, and FT-ONO2 for the treatment of advanced solid tumors.
Featured Article: What does a neutral rating on stocks mean?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]
15 Healthcare Stocks that Analysts Love
There are more than 200 healthcare companies traded on public markets. Given the sheer number of pharmaceutical companies, medical research firms, hospital systems, and other healthcare stocks, it can be hard to identify which healthcare companies will outperform the market.
Fortunately, Wall Street’s brightest minds have already done this for us. Every year, analysts issue approximately 3,000 distinct recommendations for healthcare companies. Analysts don’t always get their “buy” ratings right, but it’s worth taking a hard look when several analysts from different brokerages and research firms are giving “strong-buy” and “buy” ratings to the same healthcare stock.
This slide show lists the 15 healthcare companies with the highest average analyst recommendations from Wall Street’s equities research analysts over the last 12 months.
Published at Sat, 20 Feb 2021 09:56:15 +0000